Cargando…
Decision-making for PCV in adults
Thirteen-valent pneumococcal conjugate vaccine (PCV13) was licensed in adults to address the unmet medical need of vaccine-type community acquired pneumonia (CAP) and the limitations of previous plain-polysaccharide vaccines. Since then, some have questioned the utility of adult PCV13 use, arguing t...
Autores principales: | McLaughlin, John M., Swerdlow, David L., Isturiz, Raul E., Jodar, Luis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605720/ https://www.ncbi.nlm.nih.gov/pubmed/30352017 http://dx.doi.org/10.1080/21645515.2018.1538611 |
Ejemplares similares
-
Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
por: McLaughlin, John M., et al.
Publicado: (2019) -
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design
por: McLaughlin, John M, et al.
Publicado: (2018) -
County-level Predictors of Coronavirus Disease 2019 (COVID-19) Cases and Deaths in the United States: What Happened, and Where Do We Go from Here?
por: McLaughlin, John M, et al.
Publicado: (2020) -
Disparities in Uptake of 13-valent Pneumococcal Conjugate Vaccine among Older Adults Following Routine Recommendation in the United States
por: McLaughlin, John, et al.
Publicado: (2017) -
1613. Rates of Hospitalization for Community-Acquired Pneumonia Among US Adults: A Systematic Review
por: McLaughlin, John M, et al.
Publicado: (2019)